```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:ssptasjl1626

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 17:14:08 ON 17 APR 2007
FILE 'CAPLUS' ENTERED AT 17:14:08 ON 17 APR 2007
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       6.21     511.91

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -0.78      -5.46

=> d his

     (FILE 'HOME' ENTERED AT 16:20:09 ON 17 APR 2007)

     FILE 'REGISTRY' ENTERED AT 16:20:17 ON 17 APR 2007
L1                STRUCTURE UPLOADED
L2              0 S L1
L3                STRUCTURE UPLOADED
L4              1 S L3
L5             35 S L3 SSS FULL
                  SAV TEM BRD565557/A L5

     FILE 'CAPLUS' ENTERED AT 16:24:21 ON 17 APR 2007
L6              6 S L5
                  SAV TEM ANS565557/A L6

     FILE 'REGISTRY' ENTERED AT 16:48:34 ON 17 APR 2007
L7                STRUCTURE UPLOADED
L8              9 S L7
L9            855 S L7 SSS FULL
                  SAV TEM BRI565557/A L9

     FILE 'STNGUIDE' ENTERED AT 16:49:43 ON 17 APR 2007

     FILE 'REGISTRY' ENTERED AT 17:03:32 ON 17 APR 2007
L10               STRUCTURE UPLOADED
L11               STRUCTURE UPLOADED
L12               STRUCTURE UPLOADED
L13            28 S L10 SSS FULL SUB=L9
                  SAV TEM FIA565557/A L13
L14             2 S L11 SSS FULL SUB=L9
                  SAV TEM FIB565557/A L14
L15             1 S L12 SSS FULL SUB=L9
                  SAV TEM FIC565557/A L15

     FILE 'CAPLUS' ENTERED AT 17:06:23 ON 17 APR 2007
L16             4 S L13
L17             1 S L14
L18             1 S L15
L19             0 S L17 NOT L16
```

L20 0 S L18 NOT L16

C:\Program Files\Stnexp\Queries\10565557-broad(2).str





chain nodes :
7 8 11 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
29 30 39 40 43 44 46 47 48 49 50 51 52 58 59 60 61 62 63
64 69 71 72 73 74 77 79
ring nodes :
1 2 3 4 5 6
chain bonds :
1-72 2-71 3-11 4-13 5-73 6-74 7-69 8-69 14-16 14-15 14-74 15-17
15-39 16-43 16-44 16-58 19-24 20-25 21-26 22-26 23-28 29-30 47-51
48-52 49-50 58-59 59-60 59-61 61-79 63-64
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
1-72 2-71 3-11 4-13 5-73 7-69 8-69 14-16 14-15 14-74 15-17 15-39
16-43 16-44 16-58 19-24 20-25 21-26 22-26 23-28 29-30 47-51 48-52
58-59 59-60 59-61 61-79 63-64
exact bonds :
6-74 49-50
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

G1:OH,CO2H,[*1]

G2:OH,CO2H,H,CH3

G4:[*2],[*3],[*4],[*5],[*6],[*7],[*8]

G5:H,[*9]

G6:[*10],[*11],[*12],[*13]

G7:[*14],[*15],[*16]

G8:H,CH3

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 11:CLASS
13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS
27:Atom 28:Atom 29:CLASS 30:CLASS 39:CLASS 40:CLASS 43:CLASS
44:CLASS 46:Atom 47:Atom 48:Atom 49:Atom 50:Atom 51:Atom 52:Atom
58:CLASS 59:CLASS 60:CLASS 61:CLASS 62:CLASS 63:CLASS 64:Atom
69:CLASS 71:CLASS 72:CLASS 73:CLASS 74:CLASS 77:Atom 79:CLASS

Generic attributes :
40:
Saturation : Saturated
47:
Saturation : Unsaturated
48:
Saturation : Unsaturated
49:
Saturation : Unsaturated
50:
Saturation : Unsaturated
51:
Saturation : Unsaturated
52:
Saturation : Unsaturated
64:
Type of Ring System : Monocyclic
69:
Type of chain : Linear
Saturation : Saturated

C:\Program Files\Stnexp\Queries\10565557-broad(3).str





chain nodes :
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 32 33 36
37 39 40 41 42 43 44 45 51 52 53 54 55 56 57 63 66 68
ring nodes :
1 2 3 4 5 6
chain bonds :
6-63 7-9 7-8 7-63 8-10 8-32 9-36 9-37 9-51 12-17 13-18 14-19
15-19 16-21 22-23 40-44 41-45 42-43 51-52 52-53 52-54 54-68 56-57
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
7-9 7-8 7-63 8-10 8-32 9-36 9-37 9-51 12-17 13-18 14-19 15-19
16-21 22-23 40-44 41-45 51-52 52-53 52-54 54-68 56-57
exact bonds :
6-63 42-43
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

G4:[*1],[*2],[*3],[*4],[*5],[*6],[*7]

G5:H,[*8]

G6:[*9],[*10],[*11],[*12]

G7:[*13],[*14],[*15]

G8:H,CH3

G9:O

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS
17:CLASS 18:CLASS 19:CLASS 20:Atom 21:Atom 22:CLASS 23:CLASS
32:CLASS 33:CLASS 36:CLASS 37:CLASS 39:Atom 40:Atom 41:Atom 42:Atom
43:Atom 44:Atom 45:Atom 51:CLASS 52:CLASS 53:CLASS 54:CLASS 55:CLASS
56:CLASS 57:Atom 63:CLASS 66:Atom 68:CLASS

Generic attributes :

33:
Saturation : Saturated
40:
Saturation : Unsaturated
41:
Saturation : Unsaturated
42:
Saturation : Unsaturated
43:
Saturation : Unsaturated
44:
Saturation : Unsaturated
45:
Saturation : Unsaturated
57:
Type of Ring System : Monocyclic

C:\Program Files\Stnexp\Queries\10565557-formula(IA).str





chain nodes :
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 32 33 36
37 39 40 41 42 43 44 45 51 52 53 54 55 56 57 62 65 67 68
69
ring nodes :
1 2 3 4 5 6
chain bonds :
3-68 6-62 7-9 7-8 7-62 8-10 8-32 9-36 9-37 9-51 12-17 13-18
14-19 15-19 16-21 22-23 40-44 41-45 42-43 51-52 52-53 52-54 54-67
56-57
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
3-68 7-9 7-8 7-62 8-10 8-32 9-36 9-37 9-51 12-17 13-18 14-19
15-19 16-21 22-23 40-44 41-45 51-52 52-53 52-54 54-67 56-57
exact bonds :
6-62 42-43
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

G4:[*1],[*2],[*3],[*4],[*5],[*6],[*7]

G5:H,[*8]

G6:[*9],[*10],[*11],[*12]

G7:[*13],[*14],[*15]

G8:H,CH3

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS
17:CLASS 18:CLASS 19:CLASS 20:Atom 21:Atom 22:CLASS 23:CLASS
32:CLASS 33:CLASS 36:CLASS 37:CLASS 39:Atom 40:Atom 41:Atom 42:Atom
43:Atom 44:Atom 45:Atom 51:CLASS 52:CLASS 53:CLASS 54:CLASS 55:CLASS
56:CLASS 57:Atom 62:CLASS 65:Atom 67:CLASS 68:CLASS 69:CLASS 70:Atom

Generic attributes :

33:
Saturation : Saturated
40:
Saturation : Unsaturated
41:
Saturation : Unsaturated
42:
Saturation : Unsaturated
43:
Saturation : Unsaturated
44:
Saturation : Unsaturated
45:
Saturation : Unsaturated
57:
Type of Ring System : Monocyclic

C:\Program Files\Stnexp\Queries\10565557-formula(IB).str



chain nodes :
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 32 33 36
37 39 40 41 42 43 44 45 51 52 53 54 55 56 57 62 65 67 68
69
ring nodes :
1 2 3 4 5 6
chain bonds :
3-68 6-62 7-9 7-8 7-62 8-10 8-32 9-36 9-37 9-51 12-17 13-18
14-19 15-19 16-21 22-23 40-44 41-45 42-43 51-52 52-53 52-54 54-67
56-57
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
7-9 7-8 7-62 8-10 8-32 9-36 9-37 9-51 12-17 13-18 14-19 15-19
16-21 22-23 40-44 41-45 51-52 52-53 52-54 54-67 56-57
exact bonds :
3-68 6-62 42-43
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

G4:[*1],[*2],[*3],[*4],[*5],[*6],[*7]

G5:H,[*8]

G6:[*9],[*10],[*11],[*12]

G7:[*13],[*14],[*15]

G8:H,CH3

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS
17:CLASS 18:CLASS 19:CLASS 20:Atom 21:Atom 22:CLASS 23:CLASS
32:CLASS 33:CLASS 36:CLASS 37:CLASS 39:Atom 40:Atom 41:Atom 42:Atom
43:Atom 44:Atom 45:Atom 51:CLASS 52:CLASS 53:CLASS 54:CLASS 55:CLASS
56:CLASS 57:Atom 62:CLASS 65:Atom 67:CLASS 68:CLASS 69:CLASS 70:Atom

Generic attributes :

33:
Saturation : Saturated
40:
Saturation : Unsaturated
41:
Saturation : Unsaturated
42:
Saturation : Unsaturated
43:
Saturation : Unsaturated
44:
Saturation : Unsaturated
45:
Saturation : Unsaturated
57:
Type of Ring System : Monocyclic

C:\Program Files\Stnexp\Queries\10565557-formula(IC).str





chain nodes :
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 32 33 36
37 39 40 41 42 43 44 45 51 52 53 54 55 56 57 62 65 67 69
70 71
ring nodes :
1 2 3 4 5 6
chain bonds :
6-62 7-9 7-8 7-62 8-10 8-32 9-36 9-37 9-51 12-17 13-18 14-19
15-19 16-21 22-23 40-44 41-45 42-43 51-52 52-53 52-54 54-67 56-57
69-70 70-71
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
7-9 7-8 7-62 8-10 8-32 9-36 9-37 9-51 12-17 13-18 14-19 15-19
16-21 22-23 40-44 41-45 51-52 52-53 52-54 54-67 56-57 69-70
exact bonds :
6-62 42-43 70-71
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

G4:[*1],[*2],[*3],[*4],[*5],[*6],[*7]

G5:H,[*8]

G6:[*9],[*10],[*11],[*12]

G7:[*13],[*14],[*15]

G8:H,CH3

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS
17:CLASS 18:CLASS 19:CLASS 20:Atom 21:Atom 22:CLASS 23:CLASS
32:CLASS 33:CLASS 36:CLASS 37:CLASS 39:Atom 40:Atom 41:Atom 42:Atom
43:Atom 44:Atom 45:Atom 51:CLASS 52:CLASS 53:CLASS 54:CLASS 55:CLASS
56:CLASS 57:Atom 62:CLASS 65:Atom 67:CLASS 69:CLASS 70:CLASS
71:CLASS 74:Atom

Generic attributes :

33:
Saturation : Saturated
40:
Saturation : Unsaturated
41:
Saturation : Unsaturated
42:
Saturation : Unsaturated
43:
Saturation : Unsaturated
44:
Saturation : Unsaturated
45:
Saturation : Unsaturated
57:
Type of Ring System : Monocyclic

FILE 'HOME' ENTERED AT 16:20:09 ON 17 APR 2007

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:20:17 ON 17 APR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 16 APR 2007 HIGHEST RN 930395-50-9
DICTIONARY FILE UPDATES: 16 APR 2007 HIGHEST RN 930395-50-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10565557-broad.str





chain nodes :
7 8 11 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
39 40 43 44 46 47 48 49 50 51 52 58 59 60 61 62 63 64 69 71 72
73 74 77 79

ring nodes :
1 2 3 4 5 6
chain bonds :
1-72 2-71 3-11 4-13 5-73 6-74 7-69 8-69 14-16 14-15 14-74 15-17 15-39
16-43 16-44 16-58 19-24 20-25 21-26 22-26 23-28 29-30 47-51 48-52 49-50
58-59 59-60
59-61 61-79 63-64
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
1-72 2-71 3-11 4-13 5-73 6-74 7-69 8-69 14-16 14-15 14-74 15-17 15-39
16-43 16-44 16-58 19-24 20-25 21-26 22-26 23-28 29-30 47-51 48-52 58-59
59-60 59-61
61-79 63-64
exact bonds :
49-50
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

G1:OH,CO2H,[*1]

G2:OH,CO2H,H,CH3

G4:[*2],[*3],[*4],[*5],[*6],[*7],[*8]

G5:H,[*9]

G6:[*10],[*11],[*12],[*13]

G7:[*14],[*15],[*16]

G8:H,CH3

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 11:CLASS 13:CLASS
14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS 21:CLASS
22:CLASS 23:CLASS
24:CLASS 25:CLASS 26:CLASS 27:Atom 28:Atom 29:CLASS 30:CLASS 39:CLASS
40:CLASS 43:CLASS
44:CLASS 46:Atom 47:Atom 48:Atom 49:Atom 50:Atom 51:Atom 52:Atom 58:CLASS
59:CLASS 60:CLASS
61:CLASS 62:CLASS 63:CLASS 64:Atom 69:CLASS 71:CLASS 72:CLASS 73:CLASS
74:CLASS 77:Atom
79:CLASS
Generic attributes :
40:
Saturation : Saturated
47:
Saturation : Unsaturated
48:
Saturation : Unsaturated
49:
Saturation : Unsaturated
50:
Saturation : Unsaturated
51:
Saturation : Unsaturated
52:
Saturation : Unsaturated
64:
Type of Ring System : Monocyclic
69:
Type of chain : Linear
Saturation : Saturated

L1 STRUCTURE UPLOADED

=> s l1
SAMPLE SEARCH INITIATED 16:20:52 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 58889 TO ITERATE

3.4% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1163315 TO 1192245
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=>
Uploading C:\Program Files\Stnexp\Queries\10565557-broad(2).str

chain nodes :
7 8 11 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
39 40 43 44 46 47 48 49 50 51 52 58 59 60 61 62 63 64 69 71 72
73 74 77 79

ring nodes :
1 2 3 4 5 6
chain bonds :
1-72 2-71 3-11 4-13 5-73 6-74 7-69 8-69 14-16 14-15 14-74 15-17 15-39
16-43 16-44 16-58 19-24 20-25 21-26 22-26 23-28 29-30 47-51 48-52 49-50
58-59 59-60
59-61 61-79 63-64
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
1-72 2-71 3-11 4-13 5-73 7-69 8-69 14-16 14-15 14-74 15-17 15-39 16-43
16-44 16-58 19-24 20-25 21-26 22-26 23-28 29-30 47-51 48-52 58-59 59-60
59-61 61-79
63-64
exact bonds :
6-74 49-50
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

G1:OH,CO2H,[*1]

G2:OH,CO2H,H,CH3

G4:[*2],[*3],[*4],[*5],[*6],[*7],[*8]

G5:H,[*9]

G6:[*10],[*11],[*12],[*13]

G7:[*14],[*15],[*16]

G8:H,CH3

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 11:CLASS 13:CLASS
14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS 21:CLASS
22:CLASS 23:CLASS
24:CLASS 25:CLASS 26:CLASS 27:Atom 28:Atom 29:CLASS 30:CLASS 39:CLASS
40:CLASS 43:CLASS
44:CLASS 46:Atom 47:Atom 48:Atom 49:Atom 50:Atom 51:Atom 52:Atom 58:CLASS
59:CLASS 60:CLASS
61:CLASS 62:CLASS 63:CLASS 64:Atom 69:CLASS 71:CLASS 72:CLASS 73:CLASS
74:CLASS 77:Atom
79:CLASS
Generic attributes :
40:
Saturation : Saturated
47:
Saturation : Unsaturated
48:
Saturation : Unsaturated
49:
Saturation : Unsaturated
50:
Saturation : Unsaturated
51:
Saturation : Unsaturated
52:
Saturation : Unsaturated
64:
Type of Ring System : Monocyclic
69:
Type of chain : Linear
Saturation : Saturated

L3 STRUCTURE UPLOADED

=> s l3
SAMPLE SEARCH INITIATED 16:23:12 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 6353 TO ITERATE

31.5% PROCESSED 2000 ITERATIONS 1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 122281 TO 131839

PROJECTED ANSWERS: 1 TO 169

L4 1 SEA SSS SAM L3

=> d scan

L4 1 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzoic acid, 2-hydroxy-5-[(phenoxyacetyl)[[4-[[[(4-phenoxyphenyl)methyl]amino]carbonyl]phenyl]methyl]amino]- (9CI)
MF C36 H30 N2 O7



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s l3 sss full
FULL SEARCH INITIATED 16:23:51 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 129434 TO ITERATE

100.0% PROCESSED 129434 ITERATIONS 35 ANSWERS
SEARCH TIME: 00.00.03

L5 35 SEA SSS FUL L3

=> sav tem brd565557/a
ENTER L#, L# RANGE, ALL, OR (END):l5

=> fil caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 174.80 175.01

FILE 'CAPLUS' ENTERED AT 16:24:21 ON 17 APR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 17 Apr 2007 VOL 146 ISS 17
FILE LAST UPDATED: 15 Apr 2007 (20070415/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l5
L6 6 L5

=> d l6 tot bib abs hitstr

L6 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:87128 CAPLUS <<LOGINID::20070417>>
DN 146:177185
TI Glepp-1 inhibitors in the treatment of autoimmune and/or inflammatory disorders
IN Bombrun, Agnes; Hooft van Huijsduijnen, Rob; Jorand-Lebrun, Catherine; Vitte, Pierre-Alain; Gerber, Patrick
PA Applied Research Systems Ars Holding N. V., Neth. Antilles
SO PCT Int. Appl., 77pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007009959	A1	20070125	WO 2006-EP64288	20060714
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI EP 2005-106547	A	20050715		
US 2005-706365P	P	20050808		

OS MARPAT 146:177185
AB The present invention is related to the use of a Glepp-1 inhibitor for the manufacture of a medicament for the treatment of an autoimmune and/or an inflammatory disorder.
IT 842136-75-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Glepp-1 inhibitors in treatment of autoimmune and/or inflammatory disorders)
RN 842136-75-8 CAPLUS
CN Benzoic acid, 5-[(3-cyclopentyl-1-oxopropyl)[[4-[[[(4-phenoxyphenyl)methyl]amino]carbonyl]phenyl]methyl]amino]-2-hydroxy- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:984019 CAPLUS <<LOGINID::20070417>>
DN 143:279395
TI Methylene amide derivatives for cardiovascular disorders
IN Hooft van Huijsduijnen, Rob; Richard, Vincent
PA Apllied Research Systems Ars Holding N. V., Neth. Antilles
SO PCT Int. Appl., 75 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005082347	A1	20050909	WO 2005-EP50823	20050225
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2005216649	A1	20050909	AU 2005-216649	20050225
	CA 2554919	A1	20050909	CA 2005-2554919	20050225
	EP 1732534	A1	20061220	EP 2005-716814	20050225
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
	CN 1933827	A	20070321	CN 2005-80008722	20050225
	NO 2006004295	A	20060922	NO 2006-4295	20060922
PRAI	EP 2004-100778	A	20040227		
	WO 2005-EP50823	W	20050225		

OS MARPAT 143:279395
GI



I

AB The present invention is related to the use of substituted methylene amide derivs. for the treatment and/or prevention of cardiovascular disorders such as coronary obstruction and heart failure and/or prevention of endothelial dysfunction in heart failure.. A methylene amide derivative I was able to acutely restore endothelial function in mice with chronic heart failure.

IT 578022-53-4, 4-[[(Carboxycarbonyl)[3-[(dodecylamino)carbonyl]benzyl]amino]methyl]benzoic acid; 578022-58-9, [[3-[(Dodecylamino)carbonyl]benzyl](4-hydroxybenzyl)amino](oxo)acetic acid 578022-67-0, 4-[[(Carboxycarbonyl)[4-[(dodecylamino)carbonyl]benzyl]amino]methyl]benzoic acid 578022-93-2, [[4-[(Dodecylamino)carbonyl]benzyl](4-hydroxybenzyl)amino](oxo)acetic acid
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methylene amide derivs. for cardiovascular disorders)

RN 578022-53-4 CAPLUS

CN Benzoic acid, 4-[[(carboxycarbonyl)[[3-[(dodecylamino)carbonyl]phenyl]methyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 578022-58-9 CAPLUS

CN Acetic acid, [[[3-[(dodecylamino)carbonyl]phenyl]methyl][(4-hydroxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578022-67-0 CAPLUS

CN Benzoic acid, 4-[[(carboxycarbonyl)[[4-[(dodecylamino)carbonyl]phenyl]methyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 578022-93-2 CAPLUS
CN Acetic acid, [[[4-[(dodecylamino)carbonyl]phenyl]methyl][(4-hydroxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:120736 CAPLUS <<LOGINID::20070417>>
DN 142:219051
TI Preparation of aryl dicarboxamides as protein-tyrosine phosphatase inhibitors
IN Thomas, Russel J.; Swinnen, Dominique; Pons, Jean-Francois; Bombrun, Agnes
PA Applied Research Systems Ars Holding N.V., Neth.
SO PCT Int. Appl., 103 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005011685	A1	20050210	WO 2004-EP51558	20040720
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004260831	A1	20050210	AU 2004-260831	20040720
	CA 2529662	A1	20050210	CA 2004-2529662	20040720
	EP 1656139	A1	20060517	EP 2004-742005	20040720
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	JP 2006528157	T	20061214	JP 2006-520836	20040720
	US 2006189583	A1	20060824	US 2006-565557	20060123
	NO 2006000815	A	20060220	NO 2006-815	20060220
PRAI	EP 2003-102236	A	20030721		
	US 2003-517824P	P	20031106		
	WO 2004-EP51558	W	20040720		

OS CASREACT 142:219051; MARPAT 142:219051

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = CONHR6 wherein R6 = alkyl, alkenyl, alkynyl, cycloalkyl, etc.; X = aryl, heteroaryl, arylheteroaryl, arylaryl, etc.; n = 0 or 1; R1 and R2 independently = H or alkyl; R3 = alkyl, alkenyl, alkynyl, alkoxy, etc.; R4 and R5 independently = H, OH, alkyl, carboxy, alkoxy, etc.], and their pharmaceutically acceptable salts, are prepared and disclosed as protein-tyrosine phosphatase inhibitors. Thus, e.g., II was prepared via reductive amination of 6-amino-2,2-dimethyl-4H-1,3-benzodioxin-4-one (preparation given) with 4-formylbenzoate and subsequent amidation with 3-cyclopentylpropanoyl chloride, debenzylation, amidation with 4-phenoxybenzylamine and deprotection. I were evaluated for inhibition of PTP, and in particular PTP1B; e.g., II possessed an IC50 value of 1.0 μM in assays against PTP1B. As PTP inhibitors, I should be useful for the treatment and/or prevention of obesity and/or metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, polycystic ovary syndrome (PCOS).

IT 842136-75-8P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of aryl dicarboxamides as protein-tyrosine phosphatase (PTP) inhibitors)

RN 842136-75-8 CAPLUS

CN Benzoic acid, 5-[(3-cyclopentyl-1-oxopropyl)[[4-[[[(4-phenoxyphenyl)methyl]amino]carbonyl]phenyl]methyl]amino]-2-hydroxy- (9CI) (CA INDEX NAME)



IT 842136-78-1P 842136-83-8P 842136-84-9P
842136-85-0P 842136-86-1P 842136-87-2P
842136-88-3P 842136-89-4P 842136-90-7P
842136-91-8P 842136-93-0P 842136-95-2P
842136-97-4P 842136-99-6P 842137-01-3P
842137-03-5P 842137-04-6P 842137-05-7P
842137-07-9P 842137-09-1P 842137-11-5P
842137-13-7P 842137-14-8P 842137-15-9P
842137-17-1P 842137-18-2P 842137-19-3P
842137-20-6P 842137-21-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)
(drug candidate; preparation of aryl dicarboxamides as protein-tyrosine phosphatase (PTP) inhibitors)

RN 842136-78-1 CAPLUS
CN D-Glucitol, 1-deoxy-1-(methylamino)-, 5-[(3-cyclopentyl-1-oxopropyl)[[4-[[[(4-phenoxyphenyl)methyl]amino]carbonyl]phenyl]methyl]amino]-2-hydroxybenzoate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 842136-75-8
CMF C36 H36 N2 O6



CM 2

CRN 6284-40-8
CMF C7 H17 N O5

Absolute stereochemistry.



RN 842136-83-8 CAPLUS
CN Benzoic acid, 5-[(3-cyclopentyl-1-oxopropyl)[[4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl]amino]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 842136-84-9 CAPLUS
CN Benzoic acid, 2-hydroxy-5-[[[4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl][4-(trifluoromethyl)benzoyl]amino]- (9CI) (CA INDEX NAME)



RN 842136-85-0 CAPLUS
CN Benzoic acid, 2-hydroxy-5-[(1-oxo-3-phenylpropyl)[[4-[[[(4-phenoxyphenyl)methyl]amino]carbonyl]-2-thiazolyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 842136-86-1 CAPLUS
CN Benzoic acid, 5-[benzoyl[[4-[[[(4-phenoxyphenyl)methyl]amino]carbonyl]-2-thiazolyl]methyl]amino]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 842136-87-2 CAPLUS

CN Benzoic acid, 2-hydroxy-5-[[[4-[[[(4-phenoxyphenyl)methyl]amino]carbonyl]-2-thiazolyl]methyl][4-(trifluoromethyl)benzoyl]amino]- (9CI) (CA INDEX NAME)



RN 842136-88-3 CAPLUS
CN Benzoic acid, 5-[(cyclohexylcarbonyl)[[4-[[[(4-phenoxyphenyl)methyl]amino]carbonyl]phenyl]methyl]amino]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 842136-89-4 CAPLUS
CN Benzoic acid, 2-hydroxy-5-[(1-oxo-3-phenylpropyl)[[4-[[[(4-phenoxyphenyl)methyl]amino]carbonyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 842136-90-7 CAPLUS
CN Benzoic acid, 5-[benzoyl[[4-[[[(4-phenoxyphenyl)methyl]amino]carbonyl]phenyl]methyl]amino]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 842136-91-8 CAPLUS
CN Benzoic acid, 5-[acetyl[[4-[[[(4-phenoxyphenyl)methyl]amino]carbonyl]phenyl]methyl]amino]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 842136-93-0 CAPLUS
CN Benzoic acid, 5-[(4-cyanobenzoyl)[[4-[[[(4-phenoxyphenyl)methyl]amino]carbonyl]phenyl]methyl]amino]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 842136-95-2 CAPLUS
CN Benzoic acid, 2-hydroxy-5-[(phenoxyacetyl)[[4-[[[(4-phenoxyphenyl)methyl]amino]carbonyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 842136-97-4 CAPLUS
CN Benzoic acid, 2-hydroxy-5-[[[4-[[[(4-phenoxyphenyl)methyl]amino]carbonyl]phenyl]methyl][4-(trifluoromethyl)benzoyl]amino]- (9CI) (CA INDEX NAME)



RN 842136-99-6 CAPLUS
CN Benzoic acid, 2-hydroxy-5-[[(2E)-1-oxo-3-phenyl-2-propenyl][[4-[[[(4-phenoxyphenyl)methyl]amino]carbonyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 842137-01-3 CAPLUS
CN Benzoic acid, 5-[[(dimethylamino)acetyl][[4-[[[(4-phenoxyphenyl)methyl]amino]carbonyl]phenyl]methyl]amino]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 842137-03-5 CAPLUS
CN Benzoic acid, 2-hydroxy-5-[(3-methyl-1-oxo-2-butenyl)[[4-[[[(4-phenoxyphenyl)methyl]amino]carbonyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 842137-04-6 CAPLUS
CN Benzoic acid, 2-hydroxy-5-[[[[4-[(octylamino)carbonyl]phenyl]methyl](phenoxyacetyl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 842137-05-7 CAPLUS
CN Benzoic acid, 2-hydroxy-5-[[[[4-[(octylamino)carbonyl]phenyl]methyl][4-(trifluoromethyl)benzoyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 842137-07-9 CAPLUS
CN Benzoic acid, 2-hydroxy-5-[[[[4-[(octylamino)carbonyl]phenyl]methyl][(2E)-1-oxo-3-phenyl-2-propenyl]amino]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 842137-09-1 CAPLUS
CN Benzoic acid, 5-[[(3-cyclopentyl-1-oxopropyl)[[4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl]amino]methyl]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 842137-11-5 CAPLUS
CN Benzoic acid, 2-hydroxy-5-[[[[4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl](phenoxyacetyl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 842137-13-7 CAPLUS
CN Benzoic acid, 2-hydroxy-5-[[[[4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl][4-(trifluoromethyl)benzoyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 842137-14-8 CAPLUS
CN Benzoic acid, 2-hydroxy-5-[[(3-methyl-1-oxo-2-butenyl)[[4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 842137-15-9 CAPLUS
CN Benzoic acid, 5-[[(3-cyclopentyl-1-oxopropyl)[[4-[[(4-phenylbutyl)amino]carbonyl]phenyl]methyl]amino]methyl]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 842137-17-1 CAPLUS
CN Benzoic acid, 2-hydroxy-5-[[[(2E)-1-oxo-3-phenyl-2-propenyl][[4-[[[(4-pentylphenyl)methyl]amino]carbonyl]-2-thiazolyl]methyl]amino]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 842137-18-2 CAPLUS
CN Acetic acid, [4-[[[[4-[[[(4-phenoxyphenyl)methyl]amino]carbonyl]phenyl]methyl][4-(trifluoromethyl)benzoyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 842137-19-3 CAPLUS
CN Benzoic acid, 2-hydroxy-5-[(1-oxo-3-phenylpropyl)[[4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 842137-20-6 CAPLUS
CN Benzoic acid, 4-[(3-cyclopentyl-1-oxopropyl)[[4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl]amino]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 842137-21-7 CAPLUS
CN Benzoic acid, 2-hydroxy-4-[[[4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl][4-(trifluoromethyl)benzoyl]amino]- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:610410 CAPLUS <<LOGINID::20070417>>
DN 139:179889
TI Methylene amides, particularly [(arylmethyl)amino](oxo)acetic acids, useful as modulators, and especially inhibitors, of protein tyrosine

phosphatases (PTPs), and their preparation, uses, e.g., as antidiabetics, and pharmaceutical compositions.

IN Swinnen, Dominique; Bombrun, Agnes; Gonzalez, Jerome; Gerber, Patrick; Pittet, Pierre-Andre

PA Applied Research Systems ARS Holding N.V., Neth. Antilles

SO PCT Int. Appl., 346 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003064376	A1	20030807	WO 2003-EP808	20030127
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2472021	A1	20030807	CA 2003-2472021	20030127
	EP 1470102	A1	20041027	EP 2003-734697	20030127
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003007394	A	20041109	BR 2003-7394	20030127
	JP 2005516061	T	20050602	JP 2003-564000	20030127
	US 2005124656	A1	20050609	US 2003-501344	20030127
	CN 1633410	A	20050629	CN 2003-807036	20030127
	ZA 2004005179	A	20050629	ZA 2004-5179	20040629
	IN 2004DN01884	A	20070406	IN 2004-DN1884	20040701
	NO 2004003520	A	20041005	NO 2004-3520	20040824
PRAI	EP 2002-100078	A	20020129		
	EP 2002-100410	A	20020425		
	WO 2003-EP808	W	20030127		

OS MARPAT 139:179889

GI



I



II

AB Title compds. I [wherein R1 = alkyl, alkenyl, alkynyl, aryl, heteroaryl, (3-8-membered)-cycloalkyl, heterocycloalkyl, (alkyl)aryl, (alkyl)heteroaryl, (alkenyl)aryl, heteroaryl, (alkynyl)aryl, heteroaryl; R2, R3 = independently H or alkyl; Cy = aryl, heteroaryl, cycloalkyl, heterocyclyl; with the proviso that four compds. are excluded; their geometrical isomers, optically active forms as enantiomers, diastereomers and racemates, and pharmaceutically acceptable salts and active derivs.] were prepared as inhibitors of protein tyrosine phosphatases (PTPs), in particular PTP1B. Examples include over 400 invention compds., five pharmaceutical formulations, and two biol. assays. For example, II was prepared in 4 steps by amidation of 4-formylbenzoic acid with dodecylamine in THF in the presence of 4-methylmorpholine and iso-Bu chloroformate for 3 h at room temperature, reductive amination with 4-trifluoromethylbenzylamine in DCE in the presence of NaBH(OAc)3, TEA-acylation with chlorooxoacetic acid Et ester in THF, and base-catalyzed hydrolysis of the ester. II exhibited an IC50 value of 2.224 μM for inhibition of PTP1B, 1.40 μM for GLEPP-1, 2.40 μM for SHP-1, and 2.70 μM for SHP-2 in an in vitro assay. In an in vivo postprandial glycemia model in db/db mice, II, at 20-200 mg/kg orally, decreased blood glucose level by 17% at 20 mg/kg, by 42% at 100 mg/kg, and by 48% at 200 mg/kg, with decreases in serum insulin levels of -2%, 66%, and 89%, resp. Thus, I and their formulations are useful for the treatment and/or prevention of metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, polycystic ovary syndrome (PCOS).

IT 578022-53-4P, 4-[[(Carboxycarbonyl)[3-[(dodecylamino)carbonyl]benzyl]amino]methyl]benzoic acid 578022-58-9P, [[3-[(Dodecylamino)carbonyl]benzyl](4-hydroxybenzyl)amino](oxo)acetic acid 578022-67-0P, 4-[[(Carboxycarbonyl)[4-[(dodecylamino)carbonyl]benzyl]amino]methyl]benzoic acid 578022-93-2P, [[4-[(Dodecylamino)carbonyl]benzyl](4-hydroxybenzyl)amino](oxo)acetic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of [(arylmethyl)amino](oxo)acetic acids as PTP

inhibitors for antidiabetics)

RN 578022-53-4 CAPLUS

CN Benzoic acid, 4-[[(carboxycarbonyl)[[3-[(dodecylamino)carbonyl]phenyl]methyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 578022-58-9 CAPLUS

CN Acetic acid, [[[3-[(dodecylamino)carbonyl]phenyl]methyl][(4-hydroxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578022-67-0 CAPLUS

CN Benzoic acid, 4-[[(carboxycarbonyl)[[4-[(dodecylamino)carbonyl]phenyl]methyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 578022-93-2 CAPLUS

CN Acetic acid, [[[4-[(dodecylamino)carbonyl]phenyl]methyl][(4-hydroxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

not 103 b/c
112 ⇒ unpredictable activity so not motivated to add OH w/ expectation of success

L6 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:242322 CAPLUS <<LOGINID::20070417>>
DN 138:271968
TI Preparation of (heterocyclylcarbonyl)aspartic acid derivatives as caspase inhibitors
IN Choong, Ingrid; Burdett, Matthew; Delano, Warren; Erlanson, Daniel A.; Lee, Dennis; Lew, Willard
PA Sunesis Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 179 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003024955	A2	20030327	WO 2002-US29536	20020917
	WO 2003024955	A3	20030814		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003114447	A1	20030619	US 2002-245912	20020917
	US 6878743	B2	20050412		
PRAI	US 2001-323270P	P	20010918		
	US 2002-371762P	P	20020411		

OS MARPAT 138:271968
GI



I



III



IV

AB The present invention provides aspartic acid derivs. I [R1 = H, aliphatic, heteroaliph., aryl, heteroaryl, alkylaryl, alkylheteroaryl, heteroalkylaryl, heteroalkylheteroaryl; n = 0, 1; A, B, D, E, G, = independently CR, CR2, CO, S, NR, NR2, O; J = CR; each R = independently H, halo, OR2, NR22, SR2, CN, CO2R2, COR2, CONR22, SOR2, SO2R2, SO2NR22, NR2SO2R2, O2CNR22, NR2CONR22, NR2CSNR22, NR2SO2NR22, (un)substituted

aliphatic, heteroaliph., aryl, heteroaryl, alkylaryl, alkylheteroaryl, heteroalkylaryl, heteroalkylheteroaryl; R2 = independently H, halo, OR3, NR32, SR3, CN, CO2R3, COR3, CONR32, SOR3, SO2R3, SO2NR32, NR3SO2R3, O2CNR32, NR3CONR32, NR3CSNR32, NR3SO2NR32, (un)substituted aliphatic, heteroaliph., aryl, heteroaryl, alkylaryl, alkylheteroaryl, heteroalkylaryl, heteroalkylheteroaryl; R3 = H, aliphatic, heteroaliph., aryl, heteroaryl, alkylaryl, alkylheteroaryl, heteroalkylaryl, heteroalkylheteroaryl; with provisos] and pharmaceutically acceptable derivs. , and pharmaceutical compns. thereof, and methods for the use thereof as caspase inhibitors and for the treatment of disorders caused by excessive apoptotic activity (no data). Thus, Fmoc-Asp(OtBu)-CH2Br (Fmoc = 9-fluorenylmethoxycarbonyl) was coupled with 2-ClC6H4CH2SH to give sulfide Fmoc-Asp(OtBu)CH2SCH2C6H4Cl-2 (II). II was attached to a semicarbazide-derivatized Wang resin, deprotected with piperidine in DMF, coupled with Fmoc-protected aminomethylthiophenecarboxylic acid III, deprotected, and coupled with 5-chlorosulfonyl-2-hydroxybenzoic acid, and cleaved from the resin with CF3CO2H to give inhibitor IV.

IT 476362-87-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (heterocyclylcarbonyl)aspartic acid derivs. as caspase inhibitors)

RN 476362-87-5 CAPLUS

CN Benzoic acid, 5-[[acetyl[[5-[[[(1S)-1-(carboxymethyl)-3-[[(2-chlorophenyl)methyl]thio]-2-oxopropyl]amino]carbonyl]-2-thienyl]methyl]amino]methyl]-2-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2002:782787 CAPLUS <<LOGINID::20070417>>

DN 138:98

TI Identification of potent and selective small-molecule inhibitors of caspase-3 through the use of extended tethering and structure-based drug design

AU Choong, Ingrid C.; Lew, Willard; Lee, Dennis; Pham, Phuongly; Burdett, Matthew T.; Lam, Joni W.; Wiesmann, Christian; Luong, Tinh N.; Fahr, Bruce; DeLano, Warren L.; McDowell, Robert S.; Allen, Darin A.; Erlanson, Daniel A.; Gordon, Eric M.; O'Brien, Tom

CS Sunesis Pharmaceuticals Inc., South San Francisco, CA, 94080, USA

SO Journal of Medicinal Chemistry (2002), 45(23), 5005-5022
CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

OS CASREACT 138:98

GI



I



II

AB The design, synthesis, and in vitro activities of a series of potent and selective small-mol. inhibitors of caspase-3 are described. From extended tethering, a salicylic acid fragment was identified as having binding affinity for the S4 pocket of caspase-3. X-ray crystallog. and mol. modeling of the initial tethering hit resulted in the synthesis of (I), which reversibly inhibited caspase-3 with a Ki = 40 nM. Further optimization led to the identification of a series of potent and selective inhibitors with Ki values in the 20-50 nM range. One of the most potent compds. in this series, (II), inhibited caspase-3 with a Ki = 20 nM and selectivity of 8-500-fold for caspase-3 vs a panel of seven caspases (1, 2, and 4-8). A high-resolution X-ray cocrystal structure of I and II supports the predicted binding modes of our compds. with caspase-3.

IT 476362-87-5P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(identification of potent and selective small-mol. inhibitors of caspase-3 through the use of extended tethering and structure-based drug design)

RN 476362-87-5 CAPLUS

CN Benzoic acid, 5-[[acetyl[[5-[[[(1S)-1-(carboxymethyl)-3-[[(2-chlorophenyl)methyl]thio]-2-oxopropyl]amino]carbonyl]-2-thienyl]methyl]amino]methyl]-2-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



R6 = Et ; inclms Bz

C6-C15 alkyl &

not obvious & b/c unpredictability of modifications & structure for activity

```
RE.CNT  50    THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> d his

     (FILE 'HOME' ENTERED AT 16:20:09 ON 17 APR 2007)

     FILE 'REGISTRY' ENTERED AT 16:20:17 ON 17 APR 2007
L1              STRUCTURE UPLOADED
L2            0 S L1
L3              STRUCTURE UPLOADED
L4            1 S L3
L5           35 S L3 SSS FULL
                SAV TEM BRD565557/A L5

     FILE 'CAPLUS' ENTERED AT 16:24:21 ON 17 APR 2007
L6            6 S L5

=> sav tem ans565557/a 16

=> log hold
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      32.56     207.57

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -4.68      -4.68

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 16:25:15 ON 17 APR 2007

Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:ssptasjl1626

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 16:48:30 ON 17 APR 2007
FILE 'CAPLUS' ENTERED AT 16:48:30 ON 17 APR 2007
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      32.56     207.57

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -4.68      -4.68

=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      32.56     207.57

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
```

CA SUBSCRIBER PRICE -4.68 -4.68

FILE 'REGISTRY' ENTERED AT 16:48:34 ON 17 APR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 APR 2007 HIGHEST RN 930395-50-9
DICTIONARY FILE UPDATES: 16 APR 2007 HIGHEST RN 930395-50-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10565557-broad(3).str





```
chain nodes :
7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  32  33  36  37
39  40  41  42  43  44  45  51  52  53  54  55  56  57  63  66  68
ring nodes :
1  2  3  4  5  6
chain bonds :
6-63  7-9  7-8  7-63  8-10  8-32  9-36  9-37  9-51  12-17  13-18  14-19  15-19
16-21
22-23  40-44  41-45  42-43  51-52  52-53  52-54  54-68  56-57
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6
exact/norm bonds :
7-9  7-8  7-63  8-10  8-32  9-36  9-37  9-51  12-17  13-18  14-19  15-19  16-21
22-23  40-44  41-45  51-52  52-53  52-54  54-68  56-57
exact bonds :
6-63  42-43
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6
isolated ring systems :
containing 1 :


G4:[*1],[*2],[*3],[*4],[*5],[*6],[*7]

G5:H,[*8]

G6:[*9],[*10],[*11],[*12]

G7:[*13],[*14],[*15]

G8:H,CH3

G9:O

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:CLASS  10:CLASS
11:CLASS  12:CLASS  13:CLASS  14:CLASS  15:CLASS  16:CLASS  17:CLASS  18:CLASS
19:CLASS  20:Atom
21:Atom  22:CLASS  23:CLASS  32:CLASS  33:CLASS  36:CLASS  37:CLASS  39:Atom
40:Atom  41:Atom
42:Atom  43:Atom  44:Atom  45:Atom  51:CLASS  52:CLASS  53:CLASS  54:CLASS
55:CLASS  56:CLASS  57:Atom
63:CLASS  66:Atom  68:CLASS
Generic attributes :
33:
Saturation              : Saturated
40:
Saturation              : Unsaturated
41:
Saturation              : Unsaturated
42:
Saturation              : Unsaturated
43:
Saturation              : Unsaturated
44:
Saturation              : Unsaturated
45:
Saturation              : Unsaturated
57:
Type of Ring System     : Monocyclic
```

```
L7      STRUCTURE UPLOADED

=> s l7
SAMPLE SEARCH INITIATED 16:48:55 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    15766 TO ITERATE

 12.7% PROCESSED     2000 ITERATIONS                                 9 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       307800 TO   322840
PROJECTED ANSWERS:             913 TO     1923

L8            9 SEA SSS SAM L7

=> s l7 sss full
FULL SEARCH INITIATED 16:49:06 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   321203 TO ITERATE

100.0% PROCESSED   321203 ITERATIONS                             855 ANSWERS
SEARCH TIME: 00.00.08

L9          855 SEA SSS FUL L7

=> sav tem brI565557/a
ENTER L#, L# RANGE, ALL, OR (END):l9

=> fil stng
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                             172.55     380.12

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                 ENTRY    SESSION
CA SUBSCRIBER PRICE                               0.00      -4.68

FILE 'STNGUIDE' ENTERED AT 16:49:43 ON 17 APR 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Apr 13, 2007 (20070413/UP).

=> fil reg
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                               1.38     381.50

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                 ENTRY    SESSION
CA SUBSCRIBER PRICE                               0.00      -4.68

FILE 'REGISTRY' ENTERED AT 17:03:32 ON 17 APR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.
```

STRUCTURE FILE UPDATES: 16 APR 2007 HIGHEST RN 930395-50-9
DICTIONARY FILE UPDATES: 16 APR 2007 HIGHEST RN 930395-50-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10565557-formula(IA).str



chain nodes :
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 32 33 36 37
39 40 41 42 43 44 45 51 52 53 54 55 56 57 62 65 67 68 69
ring nodes :
1 2 3 4 5 6
chain bonds :
3-68 6-62 7-9 7-8 7-62 8-10 8-32 9-36 9-37 9-51 12-17 13-18 14-19 15-19
16-21 22-23 40-44 41-45 42-43 51-52 52-53 52-54 54-67 56-57
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
3-68 7-9 7-8 7-62 8-10 8-32 9-36 9-37 9-51 12-17 13-18 14-19 15-19
16-21

```
22-23  40-44  41-45  51-52  52-53  52-54  54-67  56-57
exact bonds :
6-62  42-43
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6
isolated ring systems :
containing 1 :


G4:[*1],[*2],[*3],[*4],[*5],[*6],[*7]

G5:H,[*8]

G6:[*9],[*10],[*11],[*12]

G7:[*13],[*14],[*15]

G8:H,CH3

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:CLASS  10:CLASS
11:CLASS  12:CLASS  13:CLASS  14:CLASS  15:CLASS  16:CLASS  17:CLASS  18:CLASS
19:CLASS  20:Atom
21:Atom  22:CLASS  23:CLASS  32:CLASS  33:CLASS  36:CLASS  37:CLASS  39:Atom
40:Atom  41:Atom
42:Atom  43:Atom  44:Atom  45:Atom  51:CLASS  52:CLASS  53:CLASS  54:CLASS
55:CLASS  56:CLASS  57:Atom
62:CLASS  65:Atom  67:CLASS  68:CLASS  69:CLASS  70:Atom
Generic attributes :
33:
Saturation              : Saturated
40:
Saturation              : Unsaturated
41:
Saturation              : Unsaturated
42:
Saturation              : Unsaturated
43:
Saturation              : Unsaturated
44:
Saturation              : Unsaturated
45:
Saturation              : Unsaturated
57:
Type of Ring System     : Monocyclic



L10     STRUCTURE UPLOADED

=>
Uploading C:\Program Files\Stnexp\Queries\10565557-formula(IB).str
```





chain nodes :
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 32 33 36 37
39 40 41 42 43 44 45 51 52 53 54 55 56 57 62 65 67 68 69
ring nodes :
1 2 3 4 5 6
chain bonds :
3-68 6-62 7-9 7-8 7-62 8-10 8-32 9-36 9-37 9-51 12-17 13-18 14-19 15-19
16-21 22-23 40-44 41-45 42-43 51-52 52-53 52-54 54-67 56-57
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
7-9 7-8 7-62 8-10 8-32 9-36 9-37 9-51 12-17 13-18 14-19 15-19 16-21
22-23 40-44 41-45 51-52 52-53 52-54 54-67 56-57
exact bonds :
3-68 6-62 42-43
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

G4:[*1],[*2],[*3],[*4],[*5],[*6],[*7]

G5:H,[*8]

G6:[*9],[*10],[*11],[*12]

G7:[*13],[*14],[*15]

G8:H,CH3

```
Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:CLASS  10:CLASS
11:CLASS  12:CLASS  13:CLASS  14:CLASS  15:CLASS  16:CLASS  17:CLASS  18:CLASS
19:CLASS  20:Atom
21:Atom  22:CLASS  23:CLASS  32:CLASS  33:CLASS  36:CLASS  37:CLASS  39:Atom
40:Atom  41:Atom
42:Atom  43:Atom  44:Atom  45:Atom  51:CLASS  52:CLASS  53:CLASS  54:CLASS
55:CLASS  56:CLASS  57:Atom
62:CLASS  65:Atom  67:CLASS  68:CLASS  69:CLASS  70:Atom
Generic attributes :
33:
Saturation              : Saturated
40:
Saturation              : Unsaturated
41:
Saturation              : Unsaturated
42:
Saturation              : Unsaturated
43:
Saturation              : Unsaturated
44:
Saturation              : Unsaturated
45:
Saturation              : Unsaturated
57:
Type of Ring System     : Monocyclic



L11     STRUCTURE UPLOADED

=>
Uploading C:\Program Files\Stnexp\Queries\10565557-formula(IC).str
```





chain nodes :
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 32 33 36 37
39 40 41 42 43 44 45 51 52 53 54 55 56 57 62 65 67 69 70 71
ring nodes :
1 2 3 4 5 6
chain bonds :
6-62 7-9 7-8 7-62 8-10 8-32 9-36 9-37 9-51 12-17 13-18 14-19 15-19
16-21
22-23 40-44 41-45 42-43 51-52 52-53 52-54 54-67 56-57 69-70 70-71
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
7-9 7-8 7-62 8-10 8-32 9-36 9-37 9-51 12-17 13-18 14-19 15-19 16-21
22-23 40-44 41-45 51-52 52-53 52-54 54-67 56-57 69-70
exact bonds :
6-62 42-43 70-71
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

G4:[*1],[*2],[*3],[*4],[*5],[*6],[*7]

G5:H,[*8]

G6:[*9],[*10],[*11],[*12]

G7:[*13],[*14],[*15]

G8:H,CH3

```
Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:CLASS  10:CLASS
11:CLASS  12:CLASS  13:CLASS  14:CLASS  15:CLASS  16:CLASS  17:CLASS  18:CLASS
19:CLASS  20:Atom
21:Atom  22:CLASS  23:CLASS  32:CLASS  33:CLASS  36:CLASS  37:CLASS  39:Atom
40:Atom  41:Atom
42:Atom  43:Atom  44:Atom  45:Atom  51:CLASS  52:CLASS  53:CLASS  54:CLASS
55:CLASS  56:CLASS  57:Atom
62:CLASS  65:Atom  67:CLASS  69:CLASS  70:CLASS  71:CLASS  74:Atom
Generic attributes :
33:
Saturation            : Saturated
40:
Saturation            : Unsaturated
41:
Saturation            : Unsaturated
42:
Saturation            : Unsaturated
43:
Saturation            : Unsaturated
44:
Saturation            : Unsaturated
45:
Saturation            : Unsaturated
57:
Type of Ring System   : Monocyclic



L12     STRUCTURE UPLOADED

=> d his

     (FILE 'HOME' ENTERED AT 16:20:09 ON 17 APR 2007)

     FILE 'REGISTRY' ENTERED AT 16:20:17 ON 17 APR 2007
L1              STRUCTURE UPLOADED
L2            0 S L1
L3              STRUCTURE UPLOADED
L4            1 S L3
L5           35 S L3 SSS FULL
                SAV TEM BRD565557/A L5

     FILE 'CAPLUS' ENTERED AT 16:24:21 ON 17 APR 2007
L6            6 S L5
                SAV TEM ANS565557/A L6

     FILE 'REGISTRY' ENTERED AT 16:48:34 ON 17 APR 2007
L7              STRUCTURE UPLOADED
L8            9 S L7
L9          855 S L7 SSS FULL
                SAV TEM BRI565557/A L9

     FILE 'STNGUIDE' ENTERED AT 16:49:43 ON 17 APR 2007

     FILE 'REGISTRY' ENTERED AT 17:03:32 ON 17 APR 2007
L10             STRUCTURE UPLOADED
L11             STRUCTURE UPLOADED
L12             STRUCTURE UPLOADED

=> s l10 sub=l9 sss full
```

```
FULL SUBSET SEARCH INITIATED 17:04:59 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED -       60 TO ITERATE

100.0% PROCESSED       60 ITERATIONS                          28 ANSWERS
SEARCH TIME: 00.00.01

L13          28 SEA SUB=L9 SSS FUL L10

=> sav tem FIA565557/a l13

=> s l11 sub=l9 sss full
FULL SUBSET SEARCH INITIATED 17:05:31 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED -      115 TO ITERATE

100.0% PROCESSED      115 ITERATIONS                           2 ANSWERS
SEARCH TIME: 00.00.01

L14           2 SEA SUB=L9 SSS FUL L11

=> sav tem FIB565557/a l14

=> s l12 sub=l9 sss full
FULL SUBSET SEARCH INITIATED 17:06:05 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED -       92 TO ITERATE

100.0% PROCESSED       92 ITERATIONS                           1 ANSWERS
SEARCH TIME: 00.00.01

L15           1 SEA SUB=L9 SSS FUL L12

=> sav tem FIC565557/a l15

=> fil caplus
COST IN U.S. DOLLARS                        SINCE FILE      TOTAL
                                              ENTRY    SESSION
FULL ESTIMATED COST                           124.20     505.70

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)  SINCE FILE      TOTAL
                                              ENTRY    SESSION
CA SUBSCRIBER PRICE                             0.00      -4.68

FILE 'CAPLUS' ENTERED AT 17:06:23 ON 17 APR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 17 Apr 2007  VOL 146 ISS 17
FILE LAST UPDATED: 15 Apr 2007  (20070415/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html
```

```
=> d his

     (FILE 'HOME' ENTERED AT 16:20:09 ON 17 APR 2007)

     FILE 'REGISTRY' ENTERED AT 16:20:17 ON 17 APR 2007
L1                STRUCTURE UPLOADED
L2              0 S L1
L3                STRUCTURE UPLOADED
L4              1 S L3
L5             35 S L3 SSS FULL
                  SAV TEM BRD565557/A L5

     FILE 'CAPLUS' ENTERED AT 16:24:21 ON 17 APR 2007
L6              6 S L5
                  SAV TEM ANS565557/A L6

     FILE 'REGISTRY' ENTERED AT 16:48:34 ON 17 APR 2007
L7                STRUCTURE UPLOADED
L8              9 S L7
L9            855 S L7 SSS FULL
                  SAV TEM BRI565557/A L9

     FILE 'STNGUIDE' ENTERED AT 16:49:43 ON 17 APR 2007

     FILE 'REGISTRY' ENTERED AT 17:03:32 ON 17 APR 2007
L10               STRUCTURE UPLOADED
L11               STRUCTURE UPLOADED
L12               STRUCTURE UPLOADED
L13            28 S L10 SSS FULL SUB=L9
                  SAV TEM FIA565557/A L13
L14             2 S L11 SSS FULL SUB=L9
                  SAV TEM FIB565557/A L14
L15             1 S L12 SSS FULL SUB=L9
                  SAV TEM FIC565557/A L15

     FILE 'CAPLUS' ENTERED AT 17:06:23 ON 17 APR 2007

=> s l13
L16            4 L13

=> s l14
L17            1 L14

=> s l15
L18            1 L15

=> s l17 not l16
L19            0 L17 NOT L16

=> s l18 not l16
L20            0 L18 NOT L16

=> d l16 bib abs hitstr

L16  ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2007:87128  CAPLUS <<LOGINID::20070417>>
DN   146:177185
TI   Glepp-1 inhibitors in the treatment of autoimmune and/or inflammatory
     disorders
IN   Bombrun, Agnes; Hooft van Huijsduijnen, Rob; Jorand-Lebrun, Catherine;
     Vitte, Pierre-Alain; Gerber, Patrick
PA   Applied Research Systems Ars Holding N. V., Neth. Antilles
SO   PCT Int. Appl., 77pp.
```

CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007009959	A1	20070125	WO 2006-EP64288	20060714

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI EP 2005-106547 A 20050715
US 2005-706365P P 20050808
OS MARPAT 146:177185
AB The present invention is related to the use of a Glepp-1 inhibitor for the manufacture of a medicament for the treatment of an autoimmune and/or an inflammatory disorder.
IT 842136-75-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Glepp-1 inhibitors in treatment of autoimmune and/or inflammatory disorders)
RN 842136-75-8 CAPLUS
CN Benzoic acid, 5-[(3-cyclopentyl-1-oxopropyl)[[4-[[[(4-phenoxyphenyl)methyl]amino]carbonyl]phenyl]methyl]amino]-2-hydroxy- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	6.21	511.91
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.78	-5.46

```
 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 17:07:40 ON 17 APR 2007

Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:ssptasjl1626

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 17:14:08 ON 17 APR 2007
FILE 'CAPLUS' ENTERED AT 17:14:08 ON 17 APR 2007
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       6.21     511.91

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -0.78      -5.46

=> d his

     (FILE 'HOME' ENTERED AT 16:20:09 ON 17 APR 2007)

     FILE 'REGISTRY' ENTERED AT 16:20:17 ON 17 APR 2007
L1                STRUCTURE UPLOADED
L2              0 S L1
L3                STRUCTURE UPLOADED
L4              1 S L3
L5             35 S L3 SSS FULL
                  SAV TEM BRD565557/A L5

     FILE 'CAPLUS' ENTERED AT 16:24:21 ON 17 APR 2007
L6              6 S L5
                  SAV TEM ANS565557/A L6

     FILE 'REGISTRY' ENTERED AT 16:48:34 ON 17 APR 2007
L7                STRUCTURE UPLOADED
L8              9 S L7
L9            855 S L7 SSS FULL
                  SAV TEM BRI565557/A L9

     FILE 'STNGUIDE' ENTERED AT 16:49:43 ON 17 APR 2007

     FILE 'REGISTRY' ENTERED AT 17:03:32 ON 17 APR 2007
L10               STRUCTURE UPLOADED
L11               STRUCTURE UPLOADED
L12               STRUCTURE UPLOADED
L13            28 S L10 SSS FULL SUB=L9
                  SAV TEM FIA565557/A L13
L14             2 S L11 SSS FULL SUB=L9
                  SAV TEM FIB565557/A L14
L15             1 S L12 SSS FULL SUB=L9
                  SAV TEM FIC565557/A L15

     FILE 'CAPLUS' ENTERED AT 17:06:23 ON 17 APR 2007
L16             4 S L13
```

```
L17             1 S L14
L18             1 S L15
L19             0 S L17 NOT L16
L20             0 S L18 NOT L16

=> log off
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
STN INTERNATIONAL LOGOFF AT 17:14:23 ON 17 APR 2007
```